Bolman R M, Elick B, Olivari M T, Ring W S, Arentzen C E
J Heart Transplant. 1985 May;4(3):315-8.
Since 1981, at the University of Minnesota, and more recently at Washington University in St. Louis, cyclosporine has been used as the main immunosuppressive agent for heart transplantation. It was initially combined with prednisone and given in a manner similar to that described at Stanford. In late 1983, concern regarding the nephrotoxic side effects of cyclosporine were heightened due to the fact that a potential recipient had chronic renal insufficiency secondary to renal damage suffered during previous heart surgery. In this patient it was decided to use lower doses of cyclosporine and to add azathioprine to maintain adequate immunosuppression. Initially, the same prednisone therapy was employed. This patient had an uncomplicated course following heart transplantation and was discharged with a normal renal function. This experience was the origin of a trial consisting of using cyclosporine, azathioprine, and prednisone as immunotherapy for heart transplantation. This report describes the results of this therapy in 17 patients.
自1981年起，在明尼苏达大学，以及最近在圣路易斯的华盛顿大学，环孢素一直被用作心脏移植的主要免疫抑制剂。它最初与泼尼松联合使用，给药方式与斯坦福大学所描述的类似。1983年末，由于一名潜在受者因先前心脏手术中遭受的肾脏损伤而继发慢性肾功能不全，人们对环孢素的肾毒性副作用的担忧加剧。在该患者中，决定使用较低剂量的环孢素并添加硫唑嘌呤以维持足够的免疫抑制。最初，采用相同的泼尼松治疗方案。该患者心脏移植后病程顺利，出院时肾功能正常。这一经验促成了一项使用环孢素、硫唑嘌呤和泼尼松作为心脏移植免疫疗法的试验。本报告描述了该疗法在17例患者中的结果。
